tirzepatide shortage fda update Eli Lilly's Weight-Loss, Diabetes Drug Shortages Are Over, Says FDA Resolves Tirzepatide Shortage: Impact

This is a known concern with GLP-1 medications, and tirzepatide and bone loss is an active area of research

Very limited safety database (125 patients, 13 weeks)

The SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease but without diabetes

Plateau after 12 weeks typically indicates metabolic adaptation

This also means that licensed generics are expected to deliver similar effectiveness for Diabetes and weight management

Although the MHRA approved Wegovy, the brand name for semaglutide, in 2021, the drug has not yet launched in Britain as Novo Nordisk said it wanted to prioritise its supply in the US